Antifibrosis: To reverse the irreversible

Ziv Paz, Yehuda Shoenfeld*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Fibrosis is a pathological process that includes scar formation and overproduction of extracellular matrix by the connective tissue as a response to tissue damage. The fibrotic process involves multiple organs and results in progressive life-threatening diseases. Today, we know more about the molecular mechanism that leads to fibrosis involving different type of cells, cytokines, chemokines, and tissue enzymes. Fibrosis was considered an irreversible process, at least clinically, and is still usually treated by anti-inflammatory and immunosuppressive agents. No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with promising results, like: mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin. This review will provide a glance to this heavily investigated subject.

Original languageEnglish
Pages (from-to)276-286
Number of pages11
JournalClinical Reviews in Allergy and Immunology
Issue number2-3
StatePublished - Apr 2010


  • Antifibrotic therapies
  • Fibroblast
  • Fibrosis
  • IVIg
  • Profibrotic cytokines


Dive into the research topics of 'Antifibrosis: To reverse the irreversible'. Together they form a unique fingerprint.

Cite this